AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:
Please amend claims 8 and 10-14.
Please cancel claims 1, 2, 4-7 and 9.
Please add new claims 18-26.

1-7. **(Canceled)**

8. **(Currently Amended)** A method of treating a subject suffering from ~~a TNFα-related disorder, wherein the TNFα-related disorder is~~ psoriasis, comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of ~~administering a therapeutically effective amount of a~~ an anti-TNFα antibody, or an antigen-binding fragment thereof, that ~~to the subject, wherein the antibody~~ dissociates from human TNFα with a K_d of 1×10^{-8} M or less and a K_{off} rate constant of 1×10^{-3} s^{-1} or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard *in vitro* L929 assay with an IC_{50} of 1×10^{-7} M or less, such that said psoriasis ~~TNFα-related disorder~~ is treated.

9. **(Canceled)**

10. **(Currently Amended)** A method of treating a subject suffering from ~~a TNFα-related disorder, wherein the TNFα-related disorder is~~ psoriasis, comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of ~~administering a therapeutically effective amount of a~~ an anti-TNFα antibody, or an antigen-binding fragment thereof, with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, such that said ~~TNFα-related disorder~~ psoriasis is treated.

11. **(Currently Amended)** The method of claim 8 or 10 ~~any one of claims 8, 9, or 10~~, wherein the anti-TNFα antibody is D2E7, or an antigen-binding fragment thereof.

12. **(Currently Amended)** The method of claim 8 or 10 ~~any one of claims 8, 9, or 10~~, wherein the anti-TNFα antibody, or antigen-binding fragment thereof is administered with at least one additional therapeutic agent.

13. **(Currently Amended)** A method of treating a subject suffering from ~~a TNFα-related disorder, wherein the TNFα-related disorder is~~ psoriasis, comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of a D2E7 antibody ~~administering a therapeutically effective amount of D2E7,~~ or an antigen binding fragment thereof, such that said psoriasis ~~TNFα-related disorder~~ is treated.

14. **(Currently Amended)** The method of claim 13, wherein D2E7, or antigen binding fragment thereof, is administered with at least one additional therapeutic agent.

15-17. **(Canceled)**

18. **(New)** The method of claim 8, wherein the unit dosage form comprises 20-80 mg of the human anti-TNFa antibody, or antigen-binding fragment thereof.

19. **(New)** The method of claim 10, wherein the unit dosage form comprises 20-80 mg of the human anti-TNFa antibody, or antigen-binding fragment thereof.

20. **(New)** The method of claim 11, wherein the unit dosage form comprises 20-80 mg of D2E7, or antigen-binding fragment thereof.

21. **(New)** The method of claim 11, wherein the unit dosage form comprises 20-80 mg of D2E7.

22. **(New)** The method of claim 8, wherein the unit dosage form comprises about 40 mg of the human anti-TNFa antibody, or antigen-binding fragment thereof.

23. **(New)** The method of claim 10, wherein the unit dosage form comprises about 40 mg of the human anti-TNFa antibody, or antigen-binding fragment thereof.

24. **(New)** The method of claim 11, wherein the unit dosage form comprises about 40 mg of D2E7, or antigen-binding fragment thereof.

25. **(New)** The method of claim 11, wherein the unit dosage form comprises about 40 mg of D2E7.

26. **(New)** The method of claim 12, wherein the additional therapeutic agent is selected from the group consisting of a topical corticosteroid, a vitamin D analog and a topical or oral retinoid.